Alaunos Therapeutics, Inc. - Common stock (TCRT)
CUSIP: 98973P309
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common stock
- Shares outstanding
- 2,198,384
- Total 13F shares
- 72,015
- Share change
- -120,046
- Total reported value
- $136,970
- Price per share
- $1.90
- Number of holders
- 28
- Value change
- -$361,475
- Number of buys
- 7
- Number of sells
- 17
Quarterly Holders Quick Answers
What is CUSIP 98973P309?
CUSIP 98973P309 identifies TCRT - Alaunos Therapeutics, Inc. - Common stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 98973P309:
Top shareholders of TCRT - Alaunos Therapeutics, Inc. - Common stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| MSD Partners, L.P. |
13F
|
Company |
4.6%
|
101,010
|
$325,252 | — | 30 Sep 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.1%
|
45,348
|
$149,195 | — | 30 Sep 2024 | |
| Kevin S. Boyle Sr. |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
798,236
|
$111,993 | — | 01 Sep 2023 | |
| BlackRock, Inc. |
13F
|
Company |
1%
|
22,233
|
$71,590 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.74%
|
16,333
|
$53,746 | — | 30 Sep 2024 | |
| Raffaele Baffa |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
280,645
|
$39,374 | — | 17 May 2021 | |
| Heidi Hagen |
3/4/5
|
Director |
—
class O/S missing
|
145,889
|
$20,468 | — | 02 Sep 2021 | |
| Christopher Bowden |
3/4/5
|
Director |
—
mixed-class rows
|
144,167
mixed-class rows
|
$6,197 | — | 22 Jun 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0.06%
|
1,337
|
$4,305 | — | 30 Sep 2024 | |
| UBS Group AG |
13F
|
Company |
0.05%
|
1,028
|
$3,310 | — | 30 Sep 2024 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.04%
|
867
|
$2,781 | — | 30 Sep 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.03%
|
640
|
$2,061 | — | 30 Sep 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.02%
|
458
|
$1,507 | — | 30 Sep 2024 | |
| Sugarloaf Wealth Management, LLC |
13F
|
Company |
0.02%
|
435
|
$1,401 | — | 30 Sep 2024 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0.02%
|
426
|
$1,372 | — | 30 Sep 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.02%
|
373
|
$1,201 | — | 30 Sep 2024 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.02%
|
343
|
$1,104 | — | 30 Sep 2024 | |
| CIBC Private Wealth Group LLC |
13F
|
Company |
0.01%
|
300
|
$966 | — | 30 Sep 2024 | |
| AdvisorNet Financial, Inc |
13F
|
Company |
0.01%
|
281
|
$905 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.01%
|
237
|
$762 | — | 30 Sep 2024 | |
| Steward Partners Investment Advisory, LLC |
13F
|
Company |
0.01%
|
162
|
$522 | — | 30 Sep 2024 | |
| Na Bokf |
13F
|
Individual |
0%
|
66
|
$181 | — | 30 Sep 2024 | |
| Asset Dedication, LLC |
13F
|
Company |
0%
|
54
|
$174 | — | 30 Sep 2024 | |
| HARBOUR INVESTMENTS, INC. |
13F
|
Company |
0%
|
46
|
$148 | — | 30 Sep 2024 | |
| Newbridge Financial Services Group, Inc. |
13F
|
Company |
0%
|
24
|
$77 | — | 30 Sep 2024 | |
| SIGNATUREFD, LLC |
13F
|
Company |
0%
|
23
|
$74 | — | 30 Sep 2024 | |
| CHILTON CAPITAL MANAGEMENT LLC |
13F
|
Company |
0%
|
16
|
$52 | — | 30 Sep 2024 | |
| WEST PACES ADVISORS INC. |
13F
|
Company |
0%
|
10
|
$32 | — | 30 Sep 2024 | |
| PSI Advisors, LLC |
13F
|
Company |
0%
|
6
|
$19 | — | 30 Sep 2024 | |
| HARBOR INVESTMENT ADVISORY, LLC |
13F
|
Company |
0%
|
2
|
$6 | — | 30 Sep 2024 | |
| Tidemark, LLC |
13F
|
Company |
0%
|
2
|
$6 | — | 30 Sep 2024 | |
| TUCKER ASSET MANAGEMENT LLC |
13F
|
Company |
0%
|
1
|
$3 | — | 30 Sep 2024 | |
| Eleanor de Groot |
3/4/5
|
EVP, Operations |
—
class O/S missing
|
350,000
|
— | — | 30 Mar 2022 | |
| Abhishek K. Srivastava |
3/4/5
|
Vice President, Technical Operations |
—
class O/S missing
|
125,000
|
— | — | 15 Mar 2023 | |
| Drew Deniger |
3/4/5
|
Vice President, Research and Development |
—
class O/S missing
|
125,000
|
— | — | 15 Mar 2023 | |
| Michael Wong |
3/4/5
|
Vice President, Finance |
—
class O/S missing
|
125,000
|
— | — | 15 Mar 2023 | |
| James Huang |
3/4/5
|
Director |
—
class O/S missing
|
100,000
|
— | — | 06 Jun 2023 | |
| Mary Thistle |
3/4/5
|
Director |
—
class O/S missing
|
100,000
|
— | — | 06 Jun 2023 | |
| Robert Hofmeister |
3/4/5
|
Director |
—
class O/S missing
|
12,800
|
— | — | 06 Jun 2024 |
Institutional Holders of Alaunos Therapeutics, Inc. - Common stock (TCRT) as of Q4 2024
As of 31 Dec 2024,
Alaunos Therapeutics, Inc. - Common stock (TCRT) was held by
28 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
72,015 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, UBS Group AG, CITIGROUP INC, Tower Research Capital LLC (TRC), MORGAN STANLEY, OSAIC HOLDINGS, INC., BNP PARIBAS FINANCIAL MARKETS, and CIBC Private Wealth Group LLC.
This page lists
28
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
28
Q4 2024 holders
28
Holder diff
0
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.